Brief: EMA Says Application For Marketing Authorisation For The Advanced Therapy Medicinal Product Lumevoq Withdrawn

Gensight Biologics SA

26/04/2023 18:18

April 26 (Reuters) - Gensight Biologics SA  SIGHT.PA :
    * EMA SAYS APPLICATION FOR MARKETING AUTHORISATION FOR THE
ADVANCED THERAPY MEDICINAL PRODUCT LUMEVOQ WAS WITHDRAWN
    * EMA: CHMP RECOMMENDED GRANTING EXTENSION OF INDICATION FOR
SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5 TO INCLUDE USE AS
BOOSTER IN CHILDREN AGED 6-11 
    * EMA - CHMP RECOMMENDED OPFOLDA  FOR TREATMENT OF GLYCOGEN
STORAGE DISEASE TYPE II IN COMBINATION WITH CIPAGLUCOSIDASE ALFA


 ((Reuters.Briefs@thomsonreuters.com;))